The commonly used drugs against T. cruzi are nifurtimox and benznidazole but they both have adverse effects for humans. Clinical symptoms of Chagas disease also depends on the strain present in each region. Drug screening methods are tedious and expensive. High-throughput systems are required for screening anti-T. cruzi agents. The use of transfected parasites expressing reporter genes likě -galactosidase has facilitated drug screening. However, luciferase (luc) has a higher sensibility. In our studies we found clinical and serological differences between the Peruvian and Bolivian strain. The Bolivian strain seems more virulent as it has been documented with a high number of acute and chronic cases. Here we developed transgenic parasites expressing luciferase gene for having a new drug screening method.
Background:
The commonly used drugs against T. cruzi are nifurtimox and benznidazole but they both have adverse effects for humans. Clinical symptoms of Chagas disease also depends on the strain present in each region. Drug screening methods are tedious and expensive. High-throughput systems are required for screening anti-T. cruzi agents. The use of transfected parasites expressing reporter genes likě -galactosidase has facilitated drug screening. However, luciferase (luc) has a higher sensibility. In our studies we found clinical and serological differences between the Peruvian and Bolivian strain. The Bolivian strain seems more virulent as it has been documented with a high number of acute and chronic cases. Here we developed transgenic parasites expressing luciferase gene for having a new drug screening method.
Methods: Bolivian strain (DH29) was isolated from a child who acquired Chagas Disease by congenital infection based on microscopic examination and parasites were recovered by in vitro cultivation. The open reading frame of luc was inserted in two vectors: pBS:CL-Neo-01/BC-LacZ-10 (pLAC) and pTREX. Stable transfectans were isolated with G418 following integration of the circular transforming plasmids into the nucleus of epimastigotes by electroporation. Luciferase was detected by PCR, western blot and its activity with a luminometer.
Results: Two plasmids were developed pBS-Neo-Luc and pR-Luc-Neo. Drug (G418)-resistant parasites were isolated after three weeks post electroporation. PCR (1.7Kb) and western blot (61 KD) detected luciferase gene. Transfected parasites incubated with luciferin showed luciferase activity. The clones that failed to express luciferase were found to have integrated the neomicin gene. The clones that expressed luciferase were stable for more than six months without selection. Two clones (L95 y L97) expressing luciferase were isolated from DH29 strain. There is a correlation between the enzyme activity and number of parasites. Luciferase assay was able to detect 102 parasites ml-1.
Conclusion: The constructed plasmids pBS-Neo-Luc and el pR-Luc-Neo are useful for stable expression in T. cruzi. Two clones L95 and L97 from DH29 strain of T. cruzi expressing luciferase gene were developed.There is a linear correlation between luciferase activity and the number of parasites ml-1. Luciferase assay is able to detect at least 102 parásitos ml-1. Background: Breakthrough varicella rates range from 10 to 33%, it may be related to the regional epidemiolgy of varicella. In this study, we investigated that the effectiveness of varicella vaccine in vaccinated children who had received a single dose.
Methods: This study was conducted in 4 elementary schools and 9 nursery schools in Izmir in Turkey between October 1 and December 31, 2008. We distributed a questionnaire to parents and above to collect vaccination history and varicella disease. Varicella disease was defined as an acute, pruritic, generalized, maculopapulovesicular rash without other apparent cause and it was defined as varicella like rash that developed >6 weeks after vaccination in vaccinated children.
Results: In the study, 3630 questionnaire were distributed and 2523 of them were resumed. One thousand three hundred and eighty-four children who had received a single dose of vaccine were included the study. Exclusion criteria were: existence of incomplete questionnaire and the children who were vaccinated with two doses. The varicella history was determined in 424 patients (30.7%) among patients who received a single dose of vaccine. The mild form of varicella was found to be 65.8%, and the moderate-severe type of disease was determined in 34.2% of in this patients. The disease was diagnosed in 90 percent by a doctor. The median age of children was 95 months and the median age at vaccination was 13 months. According to the duration of vaccination, the varicella disease rate was found 15% (<5 years), and 38.4% (≥5 years). Children who had been vaccinated 10 years or more were at greater risk for varicella disease (71%) than those who had been vaccinated the more recently.
Conclusion: A single dose of varicella vaccination provided poor protection against varicella, however the vaccine provided sufficient protection against moderate and severe disease. Probability of breakthrough varicella was increased when a interval since vaccination was longer. doi:10.1016/j.ijid.2010.02.604
